FDA’s PCCP: How AI Companies Will Win the Regulatory Race

The landscape of artificial intelligence in healthcare is perpetually reshaped by innovation and, increasingly, by regulatory evolution. As Q2 2026 draws to a close, a critical analytical question for policymakers and investors alike is: How will the FDA’s Predetermined Change Control Plan (PCCP) framework fundamentally alter the competitive dynamics for AI companies, particularly as regulatory scrutiny intensifies? The answer lies in understanding which companies are best positioned to leverage this adaptive framework, moving beyond the traditional static regulatory pathways.

The PCCP Framework: A Paradigm Shift for Adaptive AI

The FDA’s Predetermined Change Control Plan (PCCP) represents a strategic move to accommodate the iterative nature of AI/ML-driven Software as a Medical Device (SaMD). Unlike conventional medical devices, AI models are designed to learn and improve over time, making frequent model updates a necessity. Historically, each significant modification to a cleared AI/ML SaMD would necessitate a new 510(k) submission or, for novel applications, a De Novo classification. This created a bottleneck, hindering the rapid deployment of improved algorithms and stifling innovation. The PCCP framework aims to alleviate this by allowing pre-approved model updates, provided the changes adhere to a predefined plan and robust quality management systems (QMS / ISO 13485) are in place. This shift signals a maturation of the FDA’s approach, moving beyond the initial SaMD Framework articulated by figures like Bakul Patel during his tenure at the FDA’s Digital Health Center of Excellence. The underlying principle is that companies with strong QA systems benefit most from this adaptive regulatory pathway. This is not merely about faster clearances; it’s about enabling continuous learning AI to reach patients more efficiently while maintaining safety and efficacy standards.

Navigating the New Regulatory Terrain: Exemplar Companies

Several AI-native companies are strategically positioned to capitalize on the PCCP framework, having already demonstrated a commitment to robust development and quality practices.

• Viz.ai: A leader in AI-powered disease detection and workflow optimization, Viz.ai’s platform is inherently designed for continuous improvement. Their extensive real-world evidence (RWE) generation and established clinical integration demonstrate a capacity for managing complex data pipelines and iterative model refinement. The PCCP could significantly streamline the deployment of enhancements to their existing cleared algorithms, such as those for stroke detection.
• HeartFlow: Specializing in AI-driven cardiovascular analysis from CT scans, HeartFlow’s solutions are built on sophisticated computational models. The ability to implement predefined changes to their algorithms without repeated premarket submissions could accelerate their expansion into new indications or refine existing diagnostic capabilities, further strengthening their patent thicket.
• Tempus AI: As a prominent player in precision medicine, Tempus AI leverages vast datasets for oncology and other therapeutic areas. Their focus on generating actionable insights from complex genomic and clinical data makes them a prime candidate for the PCCP. The framework would allow them to continuously update their predictive models as new research emerges and as their data moat expands, ensuring their AI remains cutting-edge.
• Digital Diagnostics: Known for its autonomous AI diagnostic systems, Digital Diagnostics has already navigated the De Novo pathway for novel applications. Their experience in securing clearances for AI that makes independent diagnostic determinations underscores their commitment to rigorous validation. The PCCP could enable them to evolve their diagnostic algorithms with greater agility, perhaps adapting to new disease phenotypes or improving sensitivity and specificity over time.
• Aidoc: With a broad portfolio of AI solutions for radiology, Aidoc’s products are deeply integrated into clinical workflows. Their continuous development cycle, driven by feedback from radiologists, aligns well with the PCCP’s intent. The framework would allow them to push model updates more frequently, incorporating new imaging modalities or refining detection capabilities across various pathologies without regulatory delays.

These companies exemplify the type of organization that has invested in the foundational elements, robust data governance, strong engineering practices, and a clear understanding of clinical needs, that are prerequisites for leveraging the PCCP effectively.

The Broader Context: FDA CDRH, Congress, and WHO

The FDA’s PCCP framework is not an isolated initiative but part of a broader, global effort to adapt regulatory frameworks to the unique challenges and opportunities presented by AI in healthcare. The FDA’s Center for Devices and Radiological Health (CDRH), currently led by Michelle Tarver, MD, PhD, and previously by figures like Amy Abernethy, has been at the forefront of developing innovative approaches to digital health regulation. The PCCP directly addresses the “predetermined change control” aspect outlined in the FDA’s 2019 discussion paper on AI/ML-based SaMD, which itself built upon the principles of the FDA SaMD Framework. The FDA finalized its guidance specific to AI-driven device software on December 3, 2024, and an August 2025 final PCCP guidance is in effect. FDA guidance on AI/ML SaMD regulatory considerations This regulatory evolution is also influenced by ongoing discussions in Congress regarding the oversight of AI, particularly in sensitive sectors like healthcare. Lawmakers are keen to strike a balance between fostering innovation and ensuring patient safety and algorithmic transparency. Internationally, organizations like the WHO are also developing guidelines for AI in health, recognizing the need for harmonized regulatory approaches to facilitate global access to safe and effective AI technologies. The success of the PCCP framework could serve as a valuable model for other regulatory bodies worldwide, demonstrating a viable path for managing the lifecycle of continuously learning AI. The emphasis on good machine learning practice (GMLP) and robust quality management systems is a recurring theme across these international discussions.

Investment and Policy Implications

For investors, the PCCP framework introduces a significant de-risking factor for AI companies. Those with mature QMS and a clear strategy for iterative model development will see accelerated market access for product improvements, potentially leading to faster revenue growth and stronger competitive positions. This regulatory clarity reduces the “regulatory debt” that many AI startups face, making them more attractive acquisition targets or investment opportunities. Analysis of regulatory pathways for medical AI Companies that can demonstrate a well-defined PCCP in their data room will signal a higher level of maturity and foresight to investors. For policymakers, the framework represents a crucial step in demonstrating that regulatory bodies can be agile and forward-thinking without compromising public health. It provides a mechanism to encourage responsible innovation in AI, particularly for SaMD, by rewarding companies that build quality into their development processes from the outset. The experience gained from the PCCP framework will undoubtedly inform future regulatory frameworks, not just within the FDA but potentially influencing international standards. The focus on allowing pre-approved model updates is key to preventing algorithmic drift and ensuring the continued efficacy of AI tools in dynamic clinical environments.